Alexander Shtilbans

ORCID: 0000-0002-3159-8637
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Parkinson's Disease Mechanisms and Treatments
  • Mitochondrial Function and Pathology
  • Metabolism and Genetic Disorders
  • Amyotrophic Lateral Sclerosis Research
  • Neurological disorders and treatments
  • RNA regulation and disease
  • Hereditary Neurological Disorders
  • Cardiac, Anesthesia and Surgical Outcomes
  • Intensive Care Unit Cognitive Disorders
  • Intraoperative Neuromonitoring and Anesthetic Effects
  • Genomics and Rare Diseases
  • Nerve injury and regeneration
  • Genetic Neurodegenerative Diseases
  • Peripheral Neuropathies and Disorders
  • ATP Synthase and ATPases Research
  • Neurogenetic and Muscular Disorders Research
  • Dysphagia Assessment and Management
  • Genetics, Aging, and Longevity in Model Organisms
  • Ocean Acidification Effects and Responses
  • Myasthenia Gravis and Thymoma
  • Biochemical Acid Research Studies
  • Neuroscience and Neural Engineering
  • RNA and protein synthesis mechanisms
  • Genomics and Chromatin Dynamics
  • Alzheimer's disease research and treatments

Hospital for Special Surgery
2013-2025

Cornell University
2012-2025

Weill Cornell Medicine
2021-2025

NewYork–Presbyterian Hospital
2015-2021

New York Hospital Queens
2015-2021

Presbyterian Hospital
2021

Icahn School of Medicine at Mount Sinai
2011

The Neurological Institute
2011

Columbia University Irving Medical Center
2011

Columbia University
1997-2000

Our objective was to analyze gene expression pattern in muscles from patients with amyotrophic lateral sclerosis (ALS) and multifocal motor neuropathy (MMN) compared controls. Biopsied skeletal three ALS, MMN control subjects had total RNA extracted subjected genome-wide analysis using Affymetrix GeneChip Exon 1.0 ST array. The most significant differences were confirmed RT-PCR four additional ALS patients. Results showed that over 3000 genes identified across the groups q < 10%. Among 50...

10.3109/17482968.2011.560946 article EN Amyotrophic Lateral Sclerosis 2011-03-04

In an unprecedented finding, Davis et al. [Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. Fahy, Shinobu, L. A., Galasko, D., Thal, J., Beal, M. F., Howell, N. &amp; Parker, W. Jr. (1997) Proc. Natl. Acad. Sci. USA 94, 4526–4531] used unusual DNA isolation method to show that healthy adults harbor a specific population of mutated mitochondrial cytochrome c oxidase ( COX ) genes coexist with normal mtDNAs. They reported this heteroplasmic was present at level 10–15% in the blood...

10.1073/pnas.94.26.14894 article EN Proceedings of the National Academy of Sciences 1997-12-23

The diagnosis of amyotrophic lateral sclerosis (ALS) and primary (PLS) is often difficult because a lack disease biomarkers. purpose this study was to investigate quantitative susceptibility mapping (QSM) the motor cortex as potential biomarker for ALS PLS.From retrospective database, QSM images 16 patients with upper neuron (nine men [56%], seven women; mean age, 56.3 years; 12 ALS, four PLS) 23 control (13 10 56.6 years) were reviewed. Two neuroradiologists, blinded diagnosis,...

10.2214/ajr.14.13459 article EN American Journal of Roentgenology 2015-04-23

We describe a new mitochondrial DNA mutation in the cytochrome b gene patient presenting with progressive exercise intolerance and myoglobinuria associated complex III deficiency muscle. The point results replacement of glycine at amino acid position 190 stop codon. This change predicts premature termination translation, leading to truncated protein missing 244 acids C-terminus b. fulfills all accepted criteria for pathogenicity, suggesting that this is primary cause myopathy patient. Ann...

10.1002/1531-8249(199901)45:1<127::aid-art20>3.0.co;2-y article EN Annals of Neurology 1999-01-01

A patient with progressive exercise intolerance, proximal weakness, and complex III deficiency in skeletal muscle had a missense mutation the cytochrome b gene of mitochondrial DNA (G15762A). The mutation, which leads to substitution highly conserved amino acid (G339E), was heteroplasmic (85%) patient's not present 100 individuals different ethnic backgrounds. These data strongly suggest that this molecular defect is primary cause myopathy.

10.1212/wnl.51.5.1444 article EN Neurology 1998-11-01

Abstract Background and Purpose Excessive brain iron deposition is involved in Parkinson's disease (PD) pathogenesis. However, the correlation of accumulation various nuclei not well‐established different stages disease. This cross‐sectional study aims to evaluate quantitative susceptibility mapping (QSM) as an imaging technique measure PD patients compared healthy controls. Methods Ninety‐six grouped by their Hoehn Yahr (H&amp;Y) 31 controls were included this analysis. The magnetic values...

10.1111/jon.12957 article EN Journal of Neuroimaging 2021-12-14

Background: All the processes leading to neurodegeneration cannot be addressed with just one medication. Combinations of drugs affecting various disease mechanisms concurrently could demonstrate improved effect in slowing course Parkinson’s (PD). Objective: This was a drug-repurposing experiment designed assess several combinations nine for possible added or synergistic efficacy using vitro models PD. Methods: We evaluated 44 medications (sodium phenylbutyrate, terazosin, exenatide,...

10.3390/antiox14040396 article EN cc-by Antioxidants 2025-03-27

We identified a G→A transition at nt-8363 in the mitochondrial DNA transfer ribonucleic acid Lys gene blood and muscle from 13-month-old girl who had clinical neuroradiologic evidence of Leigh syndrome died age 27 months. The mutation was less abundant same tissues patient's mother, developed myoclonus epilepsy with ragged red fibers (MERRF) her late 20s. In both mother daughter, histochemistry showed cytochrome c oxidase-negative biochemical analysis partial defects multiple...

10.1177/088307380001501109 article EN Journal of Child Neurology 2000-11-01

This study aimed to evaluate different combinations of three dietary supplements for potential additive or synergistic effects in an vitro Parkinson’s Disease model. The complex and diverse processes leading neurodegeneration each patient with a neurodegenerative disorder cannot be effectively addressed by single medication. Instead, various potentially neuroprotective agents targeting disease mechanisms simultaneously may show improved efficacy slowing the progression allowing utilized at...

10.3389/fnins.2024.1492028 article EN cc-by Frontiers in Neuroscience 2024-12-23

The HIRA family of genes (named after yeast HIR genes; is an acronym for `histone regulator') includes the HIR1 and HIR2 repressors histone gene transcription in S. cerevisiae, human TUPLE-1/HIRA, chicken HIRA, mouse HIRA. Here, we describe a new member family, Dhh, Drosophila homolog . Northern analysis with poly (A)+ mRNA isolated from different developmental stages melanogaster shows hybridization single Dhh transcript 4.1 kb. Hybridization strong female adults, unfertilized eggs...

10.1016/s0378-1119(98)00143-7 article EN cc-by-nc-nd Gene 1998-06-01

A novel A7543G mutation was found in the mitochondrial DNA transfer ribonucleic acid Asp gene an 11-year-old girl with myoclonic seizures, developmental delay, and severe behavioral problems. Muscle histochemistry failed to show any ragged red fibers or cytochrome c oxidase-negative fibers, muscle biochemistry showed partial oxidase deficiency. The heteroplasmic muscle, fibroblasts, blood from patient other affected family members, proportion of mutant correlated severity symptoms. (J Child...

10.1177/088307389901400910 article EN Journal of Child Neurology 1999-09-01

OBJECTIVE: To explore quantitative susceptibility mapping (QSM), a novel MRI technique, which quantitatively determines tissue susceptibility, primarily determined by iron content, in the motor cortex of patients with C9orf72 familial Amyotrophic Lateral Sclerosis (ALS) and controls. BACKGROUND: ALS is disease characterized progressive degeneration both upper lower neurons (UMN/LMN). There are no biomarkers for ALS. QSM has potential utility as biomarker UMN dysfunction. sensitive method to...

10.1212/wnl.84.14_supplement.p6.027 article EN Neurology 2015-04-06

We evaluate quantitative susceptibility mapping (QSM) as an MRI technique to measure brain iron accumulation in Parkinson's disease (PD) patients different stages compared healthy controls.

10.1212/wnl.96.15_supplement.2181 article EN Neurology 2021-04-13

10.3109/17482968.2011.605046 article EN Amyotrophic Lateral Sclerosis 2011-08-24
Coming Soon ...